SCHEMBL21363641

SCHEMBL21363641

Cc1nc2nc[nH]c(=O)c2n1C

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 1/20 0.44
ALDH1A1 P00352 3/20 0.44
BRD4 O60885 2/20 0.40
PDE10A Q9Y233 1/20 0.36
PNP P00491 1/20 0.35
ATAD2 Q6PL18 1/20 0.35
KDM4E B2RXH2 1/20 0.35
GAA P10253 1/20 0.35
HPGD P15428 1/20 0.35
TSHR P16473 1/20 0.35
HTT P42858 1/20 0.35
HSD17B10 Q99714 1/20 0.35
SRC P12931 1/20 0.35
PIK3CD O00329 1/20 0.34
ALPL P05186 1/20 0.34
ADORA3 P0DMS8 1/20 0.34
TMIGD3 P0DMS9 1/20 0.34
PDE4A P27815 1/20 0.34
ADORA2A P29274 1/20 0.34
ADORA2B P29275 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21363637 0.81 POLB (0.47) POLBALDH1A1BRD4PNPATAD2
SCHEMBL18704205 0.81 POLB (0.43) POLBALDH1A1BRD4PNPATAD2
SCHEMBL21393362 0.81 POLB (0.43) POLBALDH1A1BRD4PNPATAD2
SCHEMBL21353905 0.81 POLB (0.43) POLBALDH1A1BRD4PNPATAD2
SCHEMBL21393574 0.78 POLB (0.41) POLBALDH1A1BRD4PNPKDM4E
SCHEMBL21393418 0.74 SMN1; SMN2 (0.40) POLBALDH1A1HPGDTSHRHTT
SCHEMBL13199900 0.71 PNP (0.48) POLBALDH1A1BRD4PNPKDM4E
SCHEMBL21393365 0.71 CYP3A4 (0.40) POLBALDH1A1PNPKDM4EHTT
SCHEMBL14441125 0.71 ALDH1A1 (0.45) ALDH1A1ATAD2TSHRPIK3CDALPL
SCHEMBL7990063 0.70 ALDH1A1 (0.47) POLBALDH1A1BRD4KDM4EHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10710994-B2 Oxadiazole transient receptor potential channel inhibitors GENENTECH, INC. (US) 2020-07-14 US disclosed
WO-2019182925-A1 OXADIAZOLE TRANSIENT RECEPTOR POTENTIAL CHANNEL INHIBITORS GENENTECH, INC. (US) 2019-09-26 WO disclosed
US-20190284179-A1 OXADIAZOLE TRANSIENT RECEPTOR POTENTIAL CHANNEL INHIBITORS GENENTECH, INC. (US) 2019-09-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190284179-A1 OXADIAZOLE TRANSIENT RECEPTOR POTENTIAL CHANNEL INHIBITORS TRPA1, TRPV1, TRPV3 POLB 4804/4885ALDH1A1 721/4885BRD4 2349/4885
US-10710994-B2 Oxadiazole transient receptor potential channel inhibitors TRPA1, TRPV1, TRPV3 POLB 4804/4885ALDH1A1 721/4885BRD4 2349/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.